Capital Planning Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.7M | Sell |
12,415
-89
| -0.7% | -$19.7K | 0.39% | 48 |
|
|
2025
Q4 | $2.86M | Buy |
12,504
+2,279
| +22% | +$519K | 0.38% | 53 |
|
|
2025
Q3 | $2.37M | Buy |
10,225
+7,932
| +346% | +$1.62M | 0.33% | 56 |
|
|
2025
Q2 | $426K | Sell |
2,293
-20
| -0.9% | -$3.72K | 0.06% | 106 |
|
|
2025
Q1 | $485K | Sell |
2,313
-76
| -3% | -$14.8K | 0.07% | 100 |
|
|
2024
Q4 | $425K | Sell |
2,389
-4
| -0.2% | -$735 | 0.07% | 105 |
|
|
2024
Q3 | $473K | Buy |
2,393
+510
| +27% | +$95.2K | 0.07% | 100 |
|
|
2024
Q2 | $323K | Sell |
1,883
-84
| -4% | -$13.9K | 0.06% | 111 |
|
|
2024
Q1 | $358K | Sell |
1,967
-158
| -7% | -$27.2K | 0.06% | 113 |
|
|
2023
Q4 | $329K | Sell |
2,125
-17
| -0.8% | -$2.48K | 0.06% | 111 |
|
|
2023
Q3 | $319K | Buy |
2,142
+298
| +16% | +$43.7K | 0.07% | 103 |
|
|
2023
Q2 | $248K | Sell |
1,844
-114
| -6% | -$16.7K | 0.05% | 119 |
|
|
2023
Q1 | $312K | Buy |
1,958
+144
| +8% | +$22K | 0.07% | 102 |
|
|
2022
Q4 | $293K | Buy |
1,814
+178
| +11% | +$27.3K | 0.07% | 102 |
|
|
2022
Q3 | $220K | Sell |
1,636
-69
| -4% | -$9.9K | 0.06% | 116 |
|
|
2022
Q2 | $261K | Sell |
1,705
-206
| -11% | -$31.5K | 0.07% | 109 |
|
|
2022
Q1 | $310K | Buy |
1,911
+379
| +25% | +$55.1K | 0.07% | 125 |
|
|
2021
Q4 | $207K | Buy |
+1,532
| New | +$181K | 0.04% | 156 |
|
|
2019
Q3 | – | Sell |
-2,775
| Closed | -$202K | – | 152 |
|
|
2019
Q2 | $202K | Sell |
2,775
-197
| -7% | -$15.5K | 0.06% | 113 |
|
|
2019
Q1 | $240K | Sell |
2,972
-218
| -7% | -$17.8K | 0.07% | 113 |
|
|
2018
Q4 | $294K | Sell |
3,190
-630
| -16% | -$55.4K | 0.11% | 102 |
|
|
2018
Q3 | $361K | Buy |
3,820
+503
| +15% | +$47.7K | 0.12% | 103 |
|
|
2018
Q2 | $307K | Sell |
3,317
-2,086
| -39% | -$204K | 0.14% | 96 |
|
|
2018
Q1 | $511K | Buy |
5,403
+20
| +0.4% | +$2.2K | 0.18% | 93 |
|
|
2017
Q4 | $521K | Sell |
5,383
-30
| -0.6% | -$2.83K | 0.18% | 93 |
|
|
2017
Q3 | $481K | Sell |
5,413
-1,565
| -22% | -$119K | 0.19% | 92 |
|
|
2017
Q2 | $506K | Sell |
6,978
-2,531
| -27% | -$170K | 0.22% | 78 |
|
|
2017
Q1 | $620K | Sell |
9,509
-2,270
| -19% | -$143K | 0.31% | 64 |
|
|
2016
Q4 | $738K | Sell |
11,779
-7,500
| -39% | -$458K | 0.39% | 55 |
|
|
2016
Q3 | $1.22M | Hold |
19,279
| – | – | 0.65% | 38 |
|
|
2016
Q2 | $1.19M | Sell |
19,279
-465
| -2% | -$28.3K | 0.66% | 36 |
|
|
2016
Q1 | $1.13M | Buy |
19,744
+2,630
| +15% | +$147K | 0.54% | 36 |
|
|
2015
Q4 | $1.01M | Buy |
17,114
+3,300
| +24% | +$190K | 0.59% | 43 |
|
|
2015
Q3 | $752K | Buy |
13,814
+3,750
| +37% | +$244K | 0.49% | 43 |
|
|
2015
Q2 | $676K | Buy |
10,064
+5,265
| +110% | +$344K | 0.4% | 48 |
|
|
2015
Q1 | $281K | Buy |
4,799
+1,490
| +45% | +$90K | 0.2% | 81 |
|
|
2014
Q4 | $217K | Buy |
+3,309
| New | +$209K | 0.19% | 83 |
|
Other funds holding ABBV
VCM
VPM
Capital Planning Advisors's ABBV Position: Q1 2026 in Review
Capital Planning Advisors reduced its AbbVie (ABBV) stake by 0.71% in Q1 2026, selling an estimated $19.7K and leaving 12,415 shares worth $2.7M. The position accounts for 0.39% of the portfolio, ranked #48.
Capital Planning Advisors first reported a position in ABBV in Q4 2014 and has held it in 37 quarters since. The position peaked at $2.86M in Q4 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Capital Planning Advisors held 12,415 shares of AbbVie worth $2.7M as of Q1 2026.
- Capital Planning Advisors sold 89 AbbVie shares in Q1 2026, an estimated $19.7K.
- AbbVie made up 0.39% of Capital Planning Advisors's portfolio in Q1 2026, its #48 holding.
- Capital Planning Advisors first reported a position in AbbVie in Q4 2014 and has held it in 37 quarters since.
- Capital Planning Advisors's AbbVie position peaked at $2.86M in Q4 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Capital Planning Advisors's 13F filing for Q1 2026, filed 14 May 2026.